Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. (NASDAQ: HSCS) is a healthcare information technology and medical technology company focused on advancing ECG/EKG diagnostics through artificial intelligence. News related to HeartSciences often centers on the development and commercialization of its MyoVista Insights™ cloud‑native ECG management platform and its MyoVista® wavECG™ device, both designed to integrate AI‑ECG algorithms into clinical workflows.
Investors and healthcare professionals following HSCS news can find updates on regulatory milestones, such as the company’s submission of the MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance and the FDA Breakthrough Device designation granted for its aortic stenosis ECG algorithm. Company announcements also cover product enhancements, including new versions of the MyoVista Insights platform aimed at improving usability, workflow efficiency, interoperability with multiple ECG devices, and integration with hospital EHR systems.
HeartSciences’ news flow includes business updates on early adopter deployments of MyoVista Insights, commercial agreements for its AI‑ECG platform, and information about its intellectual property portfolio, including patents related to AI‑ECG algorithms and estimation of echocardiographic parameters from ECG data. Financial news items provide context on the company’s reported results and capital initiatives, as disclosed in its public filings and press releases.
By monitoring HSCS news, readers can track developments in HeartSciences’ AI‑ECG algorithms, progress in its cloud‑based ECG management solutions, and key regulatory and commercial milestones that the company reports as it works to enhance the clinical utility of ECGs in frontline and point‑of‑care cardiac screening.
HeartSciences (NASDAQ: HSCS) has secured a patent from the European Patent Office for its proprietary ECG electrode and cable connectors, enhancing its competitive position in the market. This patent builds on existing U.S. protections and aims to diversify the company's intellectual property. CEO Andrew Simpson emphasized the significance of this development as HeartSciences progresses towards commercialization of its MyoVista® device, designed to improve cardiac dysfunction diagnosis through innovative AI technology. The MyoVista® provides a dual-function ECG and is crucial for the company's recurring revenue model.
Summary not available.
HeartSciences announced the issuance of new Category III CPT codes by the American Medical Association (AMA) to support the use of AI-driven ECG risk assessments for cardiac dysfunction. Effective January 1, 2023, these codes will facilitate reimbursement and boost the adoption of the MyoVista device, currently in FDA submission. This milestone underscores the potential of AI in enhancing ECG's clinical utility, with millions of ECGs done weekly, making cardiac dysfunction detection more accessible.
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) will present at the 2022 MicroCap Rodeo Windy City Roundup Conference on October 12-13, 2022, in Chicago, Illinois. CEO Andrew Simpson is scheduled to present on October 12, at 1:30 PM CT. The presentation will be live-streamed and available for replay. Qualified investors can schedule one-on-one meetings with Mr. Simpson. The conference gathers around 60 microcap companies, offering insights into investment opportunities and trends for 2023.
HeartSciences has been granted a new patent for AI-based ECG technology to assess diastolic dysfunction, enhancing its intellectual property portfolio. This advancement positions the company to improve cardiac screening in non-specialist settings, potentially impacting over 100 million ECG tests annually in the USA. The patented MyoVista® Wavelet ECG (wavECG™) aims to provide diagnostic insights that traditional ECGs lack, addressing a critical healthcare need for early cardiac dysfunction detection. With a total of 18 patents granted globally, HeartSciences continues to innovate in medical technology.
HeartSciences (NASDAQ: HSCS; HSCSW) is approaching the completion of patient recruitment for the FDA pivotal clinical validation study of its MyoVista® wavECG™ device, having enrolled over 500 of the targeted 550 patients. The company anticipates resubmitting for FDA De Novo clearance in the current fiscal year. Following a successful IPO that raised $6.375 million, HeartSciences holds $4.3 million in cash as of July 31, 2022, sufficient to support operations through critical milestones. The global ECG market, valued at $8.3 billion in 2020, is expected to reach $18.4 billion by 2030.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS), announced its participation in the inauguration of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital on September 14, 2022. The facility aims to enhance cardiology through advanced technologies including AI. HeartSciences seeks to improve ECG diagnostic capabilities with its MyoVista device, which detects left ventricular diastolic dysfunction. This collaboration supports their FDA pivotal validation study and aligns with the hospital's commitment to innovative healthcare solutions.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS; HSCSW), announced that CEO Andrew Simpson will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. The presentation will be available for on-demand viewing starting September 12 at 7:00 AM ET. HeartSciences focuses on enhancing ECG technology with AI to improve cardiac dysfunction detection, specifically through its MyoVista device, which aims for FDA clearance. For more details, visit www.heartsciences.com.
Heart Test Laboratories, operating as HeartSciences (NASDAQ: HSCS), announced that the FDA De Novo resubmission for its MyoVista device is expected within the current fiscal year. The company has completed its IPO, raising approximately $6.375 million to strengthen its balance sheet. A pivotal clinical validation study is nearing completion, with majority patient recruitment finalized for a 575-patient trial. HeartSciences aims to revolutionize ECG testing by introducing AI-based technology for enhanced detection of cardiac dysfunction, addressing significant healthcare needs.
HeartSciences (NASDAQ: HSCS) announced that Andrew Simpson, CEO, will present at the Benzinga All Access event on July 15, 2022, at 10:00 A.M. Eastern Time. The event, which will be broadcast live, aims to provide in-depth conversations with executives across various industries. HeartSciences focuses on enhancing ECG clinical utility through AI technology, with their MyoVista device aiming for FDA clearance to improve cardiac screening, especially in point-of-care settings.
FAQ
What is the current stock price of HeartSciences (HSCS)?
What is the market cap of HeartSciences (HSCS)?
